[{"Year":2014,"Value":86.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2015,"Value":82.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2016,"Value":78.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2017,"Value":75.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2018,"Value":73.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2019,"Value":73.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2020,"Value":73.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2021,"Value":73.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3)"},{"Year":2014,"Value":92.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2015,"Value":88.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2016,"Value":78.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2017,"Value":80.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2018,"Value":76.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2019,"Value":76.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2020,"Value":76.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2021,"Value":76.0,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2)"},{"Year":2008,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2009,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2010,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2011,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2012,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2013,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2014,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2015,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2016,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2017,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2018,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"},{"Year":2019,"Value":null,"UNIT_MEASURE":"Percent","SERIES":"Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)"}]